Affymetrix announces new ChIP-on-chip array product line

By Elaine Rigoli

Tampa, Fla., March 27 - Affymetrix, Inc. announced Monday the launch of nine tiling array products for five different organisms, further expanding the industry's broadest selection of whole-genome microarrays.

Lab researchers can use the GeneChip tiling arrays to map sites of DNA-protein interaction in chromatin immunoprecipitation (ChIP)-on-chip experiments, discover new RNA transcripts or investigate global epigenomic changes like methylation or acetylation.

Affymetrix tiling arrays deliver an unbiased view of entire genomes, enabling scientists to look beyond the known protein-coding gene sequences and thoroughly study gene structure, function and regulation, according to a news release.

Scientists using the tiling arrays have reported unexpected functions for already known genes and new functions for previously unexplored parts of the genome.

"We are extremely pleased with the performance of the GeneChip tiling arrays for mapping transcription factor binding sites by ChIP-on-chip. These arrays have allowed us to comprehensively explore the non-repetitive regions of the entire human genome. This unbiased approach is already leading us to important new insights into the gene regulatory networks controlled by steroid hormones and their receptors," said Myles Brown, a medical professor at Harvard and participant in the tiling array program, in a statement.

For the past six years, Affymetrix scientists have worked to uncover broad transcriptional activity in large regions of the genome that were once considered "junk" DNA.

The arrays help to discover novel non-coding RNA transcripts and map the sites of DNA-protein interactions, officials said.

Santa Clara, Calif.-based Affymetrix develops technology for acquiring, analyzing and managing complex genetic information.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.